ST-Elevation Myocardial Infarction Following De-escalation to Aspirin Monotherapy: Evidence of Residual Platelet Function MRP4 Overexpression Dependent Case Report

Clicks: 2
ID: 314807
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #178 of 251 articles by views in European Heart Journal - Case Reports

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 251 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background De-escalation from dual antiplatelet therapy (DAPT) to aspirin monotherapy is commonly performed after percutaneous coronary intervention to reduce bleeding risk. However, interindividual variability in platelet response exists, and high-on-aspirin residual platelet reactivity may predispose to thrombotic events. Platelet overexpression of multidrug resistance protein 4 (MRP4) has been proposed as a molecular mechanism contributing to aspirin low response and it is a further risk factor for cardiovascular (CV) events. Case summary An 82-year-old woman with a history of coronary artery disease presented with ST-elevation myocardial infarction ten days after de-escalation from dual antiplatelet therapy (aspirin plus clopidogrel) to aspirin monotherapy. Coronary angiography revealed thrombotic occlusion of the proximal left anterior descending artery with in-stent restenosis. Platelet molecular analysis demonstrated increased MRP4 expression compared with aspirin-treated patients without acute coronary syndromes, suggesting impaired aspirin responsiveness consistent with a high-on-aspirin residual platelet reactivity phenotype. The patient was successfully treated with ticagrelor-based antiplatelet therapy and experienced no recurrent ischemic or bleeding events during follow-up. Conclusion This case suggests that MRP4-mediated aspirin residual platelet function may contribute to thrombotic events following de-escalation to aspirin monotherapy. Assessment of platelet reactivity and molecular markers such as MRP4 expression, before switch from dual to single therapy, may help identify individuals at higher risk of aspirin failure and support a personalized approach to antiplatelet therapy.
Reference Key
openalex_W7162203159 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors V Cesario, E Schiera, M Curreli, F Tocci, F M Pulcinelli
Journal European Heart Journal - Case Reports
Year 2026
DOI
10.1093/ehjcr/ytag385
URL
https://doi.org/10.1093/ehjcr/ytag385
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.